Tirzepatide’s Heart Benefits
Tirzepatide, known for its role in the weight loss medication Zepbound and the diabetes drug Mounjaro, is showing promise beyond just weight management. Recent research indicates it has significant effects on heart health.
Two studies examined high-risk cardiovascular patients who underwent heart procedures. Those on tirzepatide had a lower likelihood of heart attacks and related issues compared to other groups, including those using older GLP-1 medications. This reinforces tirzepatide’s potential heart-healthy advantages, alongside its reputation as the leading obesity drug in its class.
More Than Weight Loss
Tirzepatide acts by mimicking two hormones, GLP-1 and GIP, which are crucial for managing hunger, blood sugar, and metabolism.
Research consistently shows that tirzepatide can lead to greater weight loss than single-agonist GLP-1 drugs like semaglutide, with participants losing around 20% of their weight over a year. While obesity increases the risk for various health issues, including cardiovascular problems, there’s been less attention on how tirzepatide might help lower those risks.
The studies are being highlighted at this week’s joint conference by the Society for Cardiovascular Angiography & Interventions and the Canadian Association of Interventional Cardiology.
In the first study, researchers monitored patients undergoing percutaneous coronary intervention (PCI), a less invasive method for opening blocked arteries. They found that those taking tirzepatide had a 54% reduced risk of major cardiovascular events, such as heart attacks, compared to those using dulaglutide, an older GLP-1 medication.
The protective effects were still significant a year post-procedure, and participants using tirzepatide faced a lower overall mortality risk.
According to Revati Varma, an internal medicine resident at Cook County Hospital and author of the PCI study, “Tirzepatide consistently reduced major cardiovascular events and mortality across multiple time points, which clinicians should actively consider when selecting therapies.”
The second study analyzed tirzepatide’s impact on patients who had undergone aortic valve replacement. Those on tirzepatide experienced about a 30% lower risk of major cardiovascular complications, although the rate of heart attacks remained similar between both groups.
Heart Protection
Previous studies have highlighted the heart-protective qualities of GLP-1 drugs, but it’s still vital to ensure that dual agonist medications like tirzepatide provide comparable or even greater cardiovascular benefits—there was some concern that one of its components could negatively impact heart health.
Currently, tirzepatide stands out as a promising choice for individuals considering GLP-1 therapy for obesity or type 2 diabetes, even though it does usually come with a higher price tag than semaglutide. This new research indicates it could also be an effective preventative measure for those at elevated risk for heart disease.
